Gastrointestinal neuroendocrine tumors (NETs): New diagnostic and therapeutic challenges

Cancer and Metastasis Reviews

Volumn 33, Issue 1, 2014, Pages 353-359

  Castano J P ^a   Sundin, A ^b   Maecke, H R ^c   Villabona, C ^d   Vazquez Albertino, R ^e   Navarro, E ^e   Oberg K ^f  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF FREIBURG   (Germany)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Functional NET imaging; Incretin receptor (GLP 1R; GIPR); Interferon (IFN); Peptide receptor radionucleotide therapy (PRRT); PET; RECIST, SWOG, WHO criteria; Somatostatin; Somatostatin receptor; Splicing; sst5TMD4

Indexed keywords

ANGIOPEPTIN; CORTISTATIN; DOXORUBICIN; G PROTEIN COUPLED RECEPTOR; GALLIUM 68; INDIUM 111; LUTETIUM 177; OCTREOTIDE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 5; STREPTOZOCIN; TETRAXETAN; YTTRIUM 90; SOMATOSTATIN;

ARTICLE; AUTORADIOGRAPHY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; DIFFUSION WEIGHTED IMAGING; GASTROINTESTINAL TRACT; GROWTH HORMONE RELEASE; HUMAN; INTESTINE ABSORPTION; NEUROENDOCRINE TUMOR; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH SECRETION; TREATMENT RESPONSE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; DIAGNOSTIC IMAGING; GASTROINTESTINAL NEOPLASMS; IMMUNOTHERAPY; METABOLISM; NEUROENDOCRINE TUMORS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

DIAGNOSTIC IMAGING; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; NEUROENDOCRINE TUMORS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84899946126     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9465-1     Document Type: Article

References (40)

1. Oberg, K. E., Reubi, J. C., Kwekkeboom, D. J., & Krenning, E. P. (2010). Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology, 139, 742-753. 753 e741.
2. De Martino, M. C., Hofland, L. J., & Lamberts, S. W. (2010). Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Progress in Brain Research, 182, 255-280.
3. Heaney, A. P., & Melmed, S. (2004). Molecular targets in pituitary tumors. Nature Reviews Cancer, 4, 285-295.
4. Kulaksiz, H., et al. (2002). Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumors with subtype specific antibodies. Gut, 50, 52-60.
5. Culler, M. D., et al. (2011). Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer and Metastasis Reviews, 30(Suppl 1), 9-17.
6. Salazar, R., Reidy-Lagunes, D., & Yao, J. (2011). Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs, 71, 841-852.
7. Kwekkeboom, D. J., et al. (2010). Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer, 17, R53-R73.
8. Hofland, L. J., & Lamberts, S. W. (2003). The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews, 24, 28-47.
9. Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R. (2011). Resistance to somatostatin analogs in acromegaly. Endocrine Reviews, 32, 247-271.
10. Dolan, J. T., Miltenburg, D. M., Granchi, T. S., Miller, C. C., 3rd, & Brunicardi, F. C. (2001). Treatment of metastatic breast cancer with somatostatin analogues - a meta-analysis. Ann Surg Oncol, 8, 227-233.
11. Hejna, M., Schmidinger, M., & Raderer, M. (2002). The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol, 13, 653-668.
12. Duran-Prado, M., et al. (2009). Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 94, 2634-2643.
13. Cordoba-Chacon, J., et al. (2010). Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cellular and Molecular Life Sciences, 67, 1147-1163.
14. Duran-Prado, M., et al. (2012). Truncated variants of pig somatostatin receptor subtype 5 (sst5) act as dominant-negative modulators for sst2-mediated signaling. American Journal of Physiology - Endocrinology and Metabolism, 303, E1325-E1334.
15. Cordoba-Chacon, J., Gahete, M. D., Duran-Prado, M., Luque, R. M., & Castano, J. P. (2011). Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology. Annals of the New York Academy of Sciences, 1220, 6-15.
16. Duran-Prado, M., et al. (2010). A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism, 95, 2497-2502.
17. Duran-Prado, M., et al. (2012). The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene, 31, 2049-2061.
18. Li, D., et al. (2011). Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer, 117, 2863-2872.
19. Lupp, A., et al. (2011). Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinology, 94, 255-264.
20. van der Hoek, J., Lamberts, S. W., & Hofland, L. J. (2010). The somatostatin receptor subtype 5 in neuroendocrine tumors. Expert Opinion on Investigational Drugs, 19, 385-399.
21. Funa, K., Alm, G. V., Ronnblom, L., & Oberg, K. (1983). Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumors treated with leucocyte interferon. Clinical and Experimental Immunology, 53, 716-724.
22. Oberg, K., Funa, K., & Alm, G. (1983). Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. New England Journal of Medicine, 309, 129-133.
23. Platanias, L. C. (2005). Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat Rev Immunol, 5, 375-386.
24. Pavel, M. E., & Wiedenmann, B. (2011). Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Hormone and Metabolic Research, 43, 844-853.
25. Arnold, R., et al. (2005). Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clinical Gastroenterology and Hepatology, 3, 761-771.
26. Kolby, L., Persson, G., Franzen, S., & Ahren, B. (2003). Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumors. British Journal of Surgery, 90, 687-693.
27. Faiss, S., et al. (2003). Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Grou. Journal of Clinical Oncology, 21, 2689-2696.
28. Imhof, A., et al. (2011). Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of Clinical Oncology, 29, 2416-2423.
29. Ginj, M., et al. (2005). Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res, 11, 1136-1145.
30. Hanyaloglu, A. C., & von Zastrow, M. (2008). Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annual Review of Pharmacology and Toxicology, 48, 537-568.
31. Cescato, R., Waser, B., Fani, M., & Reubi, J. C. (2011). Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med, 52, 1886-1890.
32. Wild, D., et al. (2011). First clinical evidence that imaging with somatostatin receptor antagonists is feasible. Journal of Nuclear Medicine, 52, 1412-1417.
33. Wild, D., Macke, H., Christ, E., Gloor, B., & Reubi, J. C. (2008). Glucagon-like peptide 1-receptor scans to localize occult insulinomas. New England Journal of Medicine, 359, 766-768.
34. Christ, E., et al. (2009). Glucagon-like peptide-1 receptor imaging for localization of insulinomas. Journal of Clinical Endocrinology and Metabolism, 94, 4398-4405.
35. Waser, B., Rehmann, R., Sanchez, C., Fourmy, D., & Reubi, J. C. (2012). Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism, 97, 482-488.
36. Burzykowski, T., et al. (2008). Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology, 26, 1987-1992.
37. Choi, H., et al. (2007). Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Journal of Clinical Oncology, 25, 1753-1759.
38. Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009). From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. Journal of Nuclear Medicine, 50(Suppl 1), 122S-150S.
39. Gabriel, M., et al. (2009). 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. Journal of Nuclear Medicine, 50, 1427-1434.
40. Velilyan, I., et al. (2010). In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumors - impact of peptide mass. Nuclear Medicine and Biology, 37, 265-275.